No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 24 of the 34 quarters in the window, leaving 10 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 2.4x · 10Y median 19.2x · 9th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 35
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T20:59:07.479Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Verrica Pharmaceuticals Inc. (VRCA) stock was $4.21 as of Oct 6, 2026, 4:00 PM EDT, down 2.32% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -7.7% · 3-year avg -52.2%/yr · 5-year avg -48.7%/yr
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Biotechnology · West Chester, PA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-0.50
Revenue Est.
$6.41M
Last Quarter Results
EPS
$-0.62
vs Estimate
$-0.39
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1VRCA | $72.32M | $4.21 | -2.32% | -7.67% | -48.68% | N/A | N/A |
| 2HYFT | $72.83M | $1.55 | +4.03% | -11.78% | -23.93% | N/A | vs VRCA |
| 3HYPR | $73.27M | $0.87 | -1.46% | -40.20% | -38.34% | N/A | vs VRCA |
| 4GANX | $71.23M | $1.67 | -1.18% | -11.93% | -25.06% | N/A | vs VRCA |
| 5TLSA | $70.63M | $1.11 | +3.74% | -45.53% | -5.37% | N/A | vs VRCA |
| 6CSBR | $69.61M | $5.01 | +0.80% | -21.02% | -13.07% | +12.07% | vs VRCA |
forward FY estimate
N/A
$5.86M
vs Estimate
$5.73M
Consensus Rating
Based on 6 analysts
Average Price Target
$13.83
+228.6% upside
Low
$9.00
Current
$4.21
High
$20.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.62 | $-0.50 | $-0.41 | 2 |
| Quarter ending Dec 2026 | $-0.59 | $-0.48 | $-0.39 | 2 |
| Quarter ending Mar 2027 | $-0.66 | $-0.54 | $-0.44 | 1 |
| Quarter ending Jun 2027 | $-0.54 | $-0.44 | $-0.36 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.55 | $-2.04 | $-1.61 | 3 |
| FY 2027 | $-1.67 | $-1.34 | $-1.06 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $5.63M | $6.41M | $7.20M | 4 |
| Quarter ending Dec 2026 | $6.70M | $7.52M | $8.35M | 4 |
| Quarter ending Mar 2027 | $6.47M | $7.50M | $8.86M | 2 |
| Quarter ending Jun 2027 | $7.77M | $9.00M | $10.64M | 2 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $23.25M | $24.82M | $26.38M | 5 |
| FY 2027 | $33.50M | $39.22M | $44.93M | 5 |
